Business Services Industry

US Patent Office Denies Third Party Reexamination Request Of Key PharmaStem Patent Claims

Business Wire, May 9, 2005

WAYNE, Pa. -- PharmaStem Therapeutics, Inc. announced today that the United States Patent Office has confirmed key patent claims in two of its pioneering patents. In Office communications, the Patent Office stated that the prior art cited by third parties did not raise a new question of patentability of these claims. These Office communications were prompted by reexamination requests that had been filed with the Patent Office.

"I am gratified that the Patent Office reached an early and positive conclusion regarding the key claims in Patents 6,461,645 and 6,569,427," said Nicholas Didier, CEO and President of PharmaStem. "I am confident that the Patent Office will also confirm all additional claims in these and other PharmaStem patents in the near future."

PharmaStem is the successor to Biocyte Corporation, and the pioneer in the development of umbilical cord blood preservation and its therapeutic use. Umbilical cord and placental blood are rich in stem cells that can reconstitute human blood and immune systems. The Company provided the roadmap for the creation of today's rapidly growing field of cord blood storage for therapeutic use.

To learn more about PharmaStem Therapeutics, its patent portfolio and its licensed cord blood banks, please visit www.pharmastem.com.

COPYRIGHT 2005 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
advertisement
  • Click Here
  • Click Here
  • Click Here

Content provided in partnership with Thompson Gale